News

Special Sections

Morphosys and Galapagos Sign License Deal with Novartis in Inflammatory Disease

Morphosys and Galapagos Sign License Deal with Novartis in Inflammatory Disease

Equities Research | Equities.com |

Initial target is atopic dermatitis. Deal potentially worth $1.1 billion.


Geron's Imetelstat Reaffirmed as a Priority for Johnson & Johnson

Equities Research | Equities.com |

JNJ CEO Alex Gorsky cites hematology-related oncology among "key catalysts for growth."


SIGA Technologies Gets FDA Approval for First Smallpox Therapeutic

Equities Research | Equities.com |

Advances health security against a longstanding concern of smallpox as a potential bioterror threat. SIGA also gets priority review voucher for its next drug.


Crinetics Pharmaceuticals IPO Expected This Week For Rare Endocrine Disorders

Equities Research | Equities.com |

Initial targets include acromegaly, hyperinsulinemia and neuroendocrine tumors.


Allakos IPO Expected Next Week for Antibody Immunotherapy Programs

Equities Research | Equities.com |

Targeting receptors on eosinophils and mast cells to inhibit disease.


Zogenix Shows Positive Top-Line Results from 2nd Phase 3 Trial for Dravet Syndrome

Equities Research | Equities.com |

Confirmatory data shows significant reduction in convulsive seizures in patients with this severe form of epilepsy.


Otsuka Pharmaceuticals to Acquire Visterra for $430 Million

Equities Research | Equities.com |

Adding targeted antibody therapy platform and multiple kidney and infectious disease programs.


Constellation Pharmaceuticals Raising $80 Million in IPO to Advance Cancer Epigenetics

Equities Research | Equities.com |

Lead programs in prostate cancer, solid tumors and myelofibrosis.


Rubius Therapeutics IPO Expected Next Week to Advance Cellular Therapy Platform

Equities Research | Equities.com |

Initial focus on rare diseases, cancer and autoimmune diseases.


Liquidia Files for $50 Million IPO to Advance Drug Delivery Technology

Equities Research | Equities.com |

Lead candidates targeting pulmonary arterial hypertension and local post-operative pain.


Emerging Growth

Lexaria Bioscience Corp

Lexaria Bioscience Corp is a food sciences company. It has two distinct consumer product brands: ViPova and Lexaria Energy. It uses patent pending technology to infuse hemp oil ingredients within…

Events

The MoneyShow San Francisco

Why should you join thousands of America's savviest investors and traders who make The MoneyShow San Francisco their can't-miss conference each summer? Because you will meet face-to-face and hear from…

Learn more